Opioid Management for Discharged Emergency Department Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6+
SponsorAddinex Technologies, Inc.

About this trial

The goal of this study is to analyze the use of the Addinex system for opioid dispensing after ambulatory care to determine whether it will reduce opioid consumption, increase pill disposal, show variables that may predict opioid consumption, and determine whether this intervention is acceptable to patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Ages six years and older

Ability to swallow pills

Isolated bone fracture

Planned to receive opioids in the post-treatment period

Disqualifiers

Recent opioid use (last 30 days or 2 or more prescriptions in the past 3 months

Impaired decisional capacity

In police custody

Ward of the state

Trial design

Design model

Parallel

Treatments tested in this trial

  • Addinex

    Device

    Medication dispensing system to control and monitor opioid use

  • Standard Pill Bottle

    Device

    Access and use of opioids in a standard pill bottle.

Treatment groups

100 Participants
are divided into 4 treatment groups
Group A: Control AdultActive comparator 1 intervention
Group B: Control ChildActive comparator 1 intervention
Group C: Device AdultExperimental treatment 1 intervention
Group D: Device ChildExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Median pill consumption

Patients are expected to consume at least 16% fewer pills/MMEs using the Addinex system as compared to the control group.

Time frame
One month post treatment

Secondary outcomes

1

Median disposal of opioids

Patients are expected to dispose of at least 50% of excess opioid pills using the Addinex system vs. 20% in the control group.

Time frame
12 months post treatment

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Addinex Technologies, Inc.

Lead sponsor

National Institute on Drug Abuse (NIDA)

Collaborator